How did FBRX's revenue and expenses trend in Q4 2024?

Forte Biosciences, Inc. (FBRX) reported a net loss of $8.4 million for the quarter ended September 30, 2024, which includes revenue and expenses for Q4 2024. Here's a breakdown of its revenue and expenses trend for that quarter: 1. **Revenue Trend**: No specific revenue figures were provided for Q4 2024 in the available reports. However, considering the overall trend, it can be inferred that Forte Biosciences continued to focus on clinical development rather than generating commercial revenue during this period. 2. **Expense Trend**: The company's research and development (R&D) expenses decreased from $6.4 million in Q3 2023 to $5.9 million in Q3 2024. This reduction was primarily due to decreased manufacturing costs. General and administrative expenses also decreased from $3.8 million in Q3 2023 to $2.8 million in Q3 2024, mainly attributed to lower legal and professional expenses. Despite these reductions, Forte Biosciences reported a net loss of $8.4 million for Q4 2024, indicating that the expenses were still substantial and exceeded the revenue generated during the quarter. In summary, Forte Biosciences saw a decrease in both R&D and general and administrative expenses from the previous quarter, but continued to operate at a loss in Q4 2024, with no reported revenue for the period. The company's focus remains on clinical development and funding strategies to support its operations.